Related Experiment Video

Updated: Jun 28, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients

Adriana Morgan Oliveira1, Durvanei Augusto Maria, Martin Metzger

  • 1Laboratory of Genetics and Molecular Hematology - LIM-31, Medical School, Universidade de São Paulo, USP, 05403-000 São Paulo, Brazil.

Leukemia Research
|November 4, 2008
PubMed

Insights

Thalidomide therapy down-regulates stromal-derived factor-1alpha (SDF-1alpha) and its receptor CXCR4 in multiple myeloma. This impacts plasma cell migration and homing in patients and cell lines.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Stromal-derived factor-1alpha (SDF-1alpha) and its receptor CXCR4 are crucial for plasma cell migration and homing in multiple myeloma (MM).
  • Understanding the molecular mechanisms of MM treatment is vital for improving patient outcomes.

Purpose of the Study:

  • To investigate the effect of thalidomide therapy on the expression of SDF-1alpha and CXCR4 in multiple myeloma.

Main Methods:

  • Quantitative analysis of SDF-1alpha and CXCR4 expression in MM patients (newly diagnosed, thalidomide-treated, and other drug-treated groups).
  • In vitro study assessing SDF-1alpha and CXCR4 expression in RPMI 8226 MM cell line after thalidomide treatment.

Main Results:

  • SDF-1alpha and CXCR4 expression were significantly lower in thalidomide-treated MM patients compared to newly diagnosed or other drug-treated patients.
  • Thalidomide treatment (10 and 20 micromol/L) led to a significant decrease in SDF-1alpha and CXCR4 expression in RPMI 8226 cells.

Conclusions:

  • Thalidomide therapy induces down-regulation of the SDF-1alpha/CXCR4 axis in multiple myeloma.
  • This down-regulation may contribute to the therapeutic effects of thalidomide by affecting plasma cell homing and migration.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...